Lv11
50 积分 2023-01-29 加入
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
7小时前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer: Updated Efficacy Results from the phase 3 EMBER-3 trial
9个月前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
9个月前
已完结
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
9个月前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
9个月前
已关闭
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
9个月前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
10个月前
已完结
US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor–Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2–Low or Human Epidermal Growth Factor Receptor 2–Ultralow Breast Cancer
10个月前
已完结
US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer
10个月前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
11个月前
已完结
皖公网安备34019202002308
